| Literature DB >> 34627348 |
Liping Hou1,2, Ming Zhao2, Lijun Fan2, Bingyan Cao2, Jiajia Chen2, Yonghua Cui3, Michel Polak4, Chunxiu Gong5.
Abstract
BACKGROUND: 46, XY disorders of sex development (46, XY DSD) are congenital disorders with 46, XY chromosomal karyotype but inconsistent gonadal/phenotypic sex. One of the biggest concerns for parents and clinicians is the gender assignment. However, there is no standard uniform of care nor consensus at present. We sought to evaluate the current treatment's rationality and provide a reference basis for the gender reassignment in 46, XY DSD patients with a specific diagnosis.Entities:
Keywords: 46, XY disorders of sex development; Gender assignment; Gender dysphoria; Gender role
Mesh:
Year: 2021 PMID: 34627348 PMCID: PMC8501610 DOI: 10.1186/s13023-021-02039-1
Source DB: PubMed Journal: Orphanet J Rare Dis ISSN: 1750-1172 Impact factor: 4.303
Fig. 1Flowchart of grouping and follow-up. 5α-RD2, 5 alfa-reductase-2 deficiency; CAIS, complete androgen insensitivity syndrome; PAIS, partial androgen insensitivity syndrome; NR5A1, NR5AI gene mutation; CYP17A1, CYP17A1 gene mutation; PSAI, Pre-school Activities Inventory; CSRI, The Children's Sex Role Inventory; GD, gender dysphoria; DSM-5, diagnostic and statistical manual of mental disorders, 5th edition
The clinical manifestations of 46, XY DSD patients with different ages and etiologies
| Age | Group | n | Clinical manifestation | EMS M (QL–QU) | HCG—well-responsive n (%) | Androgen therapy # n (%) | Puberty n (%) | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Female genital with Labia mass or Cryptorchidis n (%) | *One phenotype n (%) | **Two phenotypes n (%) | ***Three phenotypes n (%) | |||||||
| 2–7 years (n = 66) | 33 | 7 (21.2%) | 4 (12.1%) | 20 (60.6%) | 2 (6.1%) | 6.0 (3.0–7.0) | 33 (100%) | 33 (100%) | – | |
| CAIS | 8 | 8 (100%) | 0 | 0 | 0 | 2.0 (0.3–2.0) | – | – | – | |
| PAIS | 12 | 1 (8.3%) | 1 (8.3%) | 8 (66.7%) | 2 (16.7%) | 4.5 (3.0–6.4) | 12 (100%) | 12 (100%) | – | |
| 7 | 1 (14.3%) | 0 | 5 (71.4%) | 1 (14.3%) | 6.0 (3.0–7.0) | 7 (100%) | 7 (100%) | – | ||
| 6 | 6 (100%) | 0 | 0 | 0 | 2.0 (2.0–2.3) | 0 | 0 | – | ||
| 8–18 years (n = 46) | 22 | 5 (22.7%) | 0 | 12 (54.5%) | 5 (22.7%) | 5.5 (3.0–7.0) | 22 (100%) | 22 (100%) | 7 (31.8%) | |
| CAIS | 8 | 8 (100%) | 0 | 0 | 0 | 2.0 (2.0–2.9) | – | – | – | |
| PAIS | 8 | 3 (37.5%) | 0 | 5 (62.5%) | 0 | 5.0 (3.0–7.0) | 8 (100%) | 7 (87.5%) | 3 (37.5%) | |
| 5 | 0 | 0 | 2 (40%) | 3 (60%) | 6.0 (5.5–7.2) | 5 (100%) | 5 (100%) | 2 (40.0%) | ||
| 3 | 2 (66.7%) | 0 | 1 (33.3%) | 0 | 2.0 (–) | 1 (33.3%) | 1 (33.3%) | 1 (33.3%) | ||
5α-RD2, 5 alfa-reductase-2 deficiency; CAIS, complete androgen insensitivity syndrome; PAIS, partial androgen insensitivity syndrome; NR5A1, NR5AI gene mutation; CYP17A1, CYP17A1 gene mutation; HCG, Human Chorionic Gonadotropin; EMS, External Masculinisation Score, the lower the score is, the higher degree of under-masculinization. #Androgen therapy administered for only 3 months before hypospadias repairmen operation.*Micro-penis or Hypospadias or Cryptorchidis;**Any two combinations of Micro-penis, Hypospadias, Cryptorchidis. ***Micro-penis, Hypospadias and Cryptorchidis
The gender reassignment in 46, XY DSD patients with different ages and etiologies
| Age | Group | n | Age of first vist (year) M (QL–QU) | Age of gender re-assignment (year) M (QL–QU) | Follow-up period (year) M (QL–QU) | Age at study (year) M (QL–QU) | Male gender at birth n (%) | Male gender after diagnosis n (%) |
|---|---|---|---|---|---|---|---|---|
| 2–7 years (n = 66) | 33 | 1.5 (0.8–2.7) | 2.0 (1.1–3.1) | 2.0 (1.4–2.5) | 4.0 (3.5–5.6) | 25 (75.7%) | 33 (100%) | |
| CAIS | 8 | 2.6 (1.9–4.6) | 2.9 (2.0–4.6) | 0.9 (0.5–1.2) | 4.1 (3.0–5.3) | 0 | 0 | |
| PAIS | 12 | 1.2 (0.7–2.1) | 1.6 (0.8–2.4) | 2.0 (1.0–3.2) | 4.0 (2.5–5.1) | 11 (91.6%) | 12 (100%) | |
| 7 | 1.0 (0.6–1.3) | 1.3 (1.0–1.5) | 2.0 (1.0–2.0) | 3.0 (2.5–3.2) | 5 (71.4%) | 7 (100%) | ||
| 6 | 1.9 (1.2–3.2) | 2.1 (1.3–4.1) | 2.6 (1.3–4.0) | 5.9 (4.0–6.7) | 0 | 0 | ||
| Control Males | 52 | – | – | – | 4.7 (4.0–5.1)a | – | – | |
| Control Females | 14 | – | – | – | 5.0 (3.3–6.2)b | – | – | |
| 8–18 years (n = 46) | 22 | 5.8 (1.0–9.7) | 6.7 (1.3–11.2) | 4.3 (1.1–7.8) | 10.6 (8.9–13.0) | 14 (63.6%) | 22 (100%) | |
| CAIS | 8 | 7.2 (1.5–8.9) | 7.9 (6.9–8.9) | 1.0 (0.7–3.1) | 9.5 (8.6–10.0) | 0 | 0 | |
| PAIS | 8 | 4.4 (2.2–6.3) | 4.6 (3.0–11.1) | 4.5 (1.7–6.3) | 10.5 (8.0–13.7) | 3 (37.5%) | 7 (87.5%) | |
| 5 | 6.1 (1.1–12.4) | 6.3 (1.9–12.9) | 1.9 (1.4–7.3) | 10.0 (8.1–14.3) | 3 (60.0%) | 5 (100%) | ||
| 3 | 12.0 (–) | 12.7 (–) | 1.9 (–) | 13.2 (–) | 1 (33.3%) | 1 (33.3%) | ||
| Control Males | 35 | – | – | – | 10.4(9.5–12.0)c | – | – | |
| Control Females | 11 | – | – | – | 10.5(9.7–12.7)d | – | – |
5α-RD2, 5 alfa-reductase-2 deficiency; CAIS, Complete androgen insensitivity syndrome; PAIS, Partial androgen insensitivity syndrome; NR5A1, NR5AI gene mutation; CYP17A1, CYP17A1 gene mutation; M, Median; QL, 25%; QU, 75%; Mann–Whitney U test was used to compare the age at study in 46, XY DSD patients and control groups. aZ score = − 1.849, p = 0.065 > 0.05; bZ score = − 0.115, p = 0.919 > 0.05; cZ score = − 0.435, p = 0.668 > 0.05; dZ score = − 0.789, p = 0.447 > 0.05
The results of PSAI in 46, XY DSD children with different etiologies (2–7 years)
| PSAI Score (24 items) | Groups (n = 66) | |||||||
|---|---|---|---|---|---|---|---|---|
| PAIS (M) n = 12 | CAIS (F) n = 8 | Control (M) n = 52 | Control (F) n = 14 | |||||
| Masculine score (QL–QU) | 38.00 (36.8–45.0) | 37.0 (34.3–42.8) | 46.0 (44.0–50.0) | 27.0 (22.5–31.5) | 29.5 (23.0–37.8) | 37.5 (34.0–41.0) | 30.0 (24.0–31.5) | |
| Feminine score (QL–QU) | 24.00 (21.0–28.0) | 25.0 (21.3–28.0) | 26.0 (19.0–29.0) | 43.0 (39.0–50.0) | 46.0 (41.0–47.3) | 26.5 (23.0–29.0) | 40.5 (35.5–47.3) | |
| PSAI score (QL–QU) | 64.75 (58.7–73.6) | 65.30 (55.1–70.5) | 69.15 (65.8–77.9) | 27.90 (26.5–34.8) | 29.00 (24.0–48.2) | 60.90 (55.9–66.7) | 32.85 (30.6–38.4) | |
| Consistency n (%) | 33 (100%) | 12 (100%) | 7 (100%) | 8 (100%) | 5 (83.3%) * | 52 (100%) | 13 (100%) | |
M, male; F, female; 5α-RD2, 5 alfa-reductase-2 deficiency; CAIS, complete androgen insensitivity syndrome; PAIS, partial androgen insensitivity syndrome; NR5A1, NR5AI gene mutation; CYP17A1, CYP17A1 gene mutation; PSAI, pre-school Activities Inventory. PSAI score = (masculine score—feminine score) × 1.1 + 48.25. The higher the PSAI score obtained, the higher the degree of masculinity
*The Chi-Square test (Fisher exact probability method) was used to compare the consistency of the gender role and assigned gender between CYP17A1 gene mutation group (assigned as female) and control females, the result showed there was no statistical difference between them (p = 0.30 > 0.05)
**The Kruskal–Wallis H test was used to compare the PSAI score between different etiologies groups and control groups. There was statistical difference between them (Chi-Square = 71.168, p < 0.001).The Mann–Whitney adjusted by Bonferroni Pairwise comparisons were performed by U-test: the PSAI score of patients with 5α-RD2 deficiency, PAIS, and NR5A1 gene mutation (assigned as male) were higher than those with CAIS and CYP17A1 gene mutation (assigned as female) (p < 0.05). The PSAI score of patients with CAIS and CYP17A1 gene mutation were similar to the control females (all p > 0.05)
Fig. 2The comparison of PSAI score of 46, XY DSD children aged 2–7 years with different etiologies. 5α-RD2, 5 alfa-reductase-2 deficiency; CAIS, complete androgen insensitivity syndrome; PAIS, partial androgen insensitivity syndrome; NR5A1, NR5AI gene mutation; CYP17A1, CYP17A1 gene mutation; PSAI, pre-school Activities Inventory. The higher the PSAI score obtained, the higher the degree of masculinity
THE comparison of CSRI score of 46, XY DSD patients with different etiologies (8–18 years)
| Groups | Gender assignment n = 46 | CSRI score (52 items) | Consistency * | |||
|---|---|---|---|---|---|---|
| Masculine score M (QL–QU) | Feminine score M (QL–QU) | CSRI score M (QL–QU) | n (%) | |||
| Male (n = 22) | 2.83 (2.65–3.18) | 3.11 (2.67–3.32) | − 0.09 (− 0.45 to 0.32) | 9 (40.9%) | 0.587** | |
| PAIS | Male (n = 7) | 3.00 (2.89–3.11) | 2.71 (2.37–2.95) | 0.29 (− 0.05 to 0.36) | 5 (71.4%) | 0.428** |
| Female (n = 1) | 2.70 (–) | 2.73 (–) | − 0.03 (–) | 1 (100%) | – | |
| CAIS | Female (n = 8) | 2.58 (2.09–2.91) | 2.86 (2.70–3.23) | − 0.28 (− 0.92 to 0.29) | 4 (50%) | 0.111*** |
| Male (n = 5) | 3.06 (2.51–3.19) | 3.00 (2.63–3.11) | 0.102 (− 0.12 to 0.22) | 3 (60%) | 1.000** | |
| Male (n = 1) | 2.90 (–) | 2.00 (–) | 0.90 (–) | 1 (100%) | – | |
| Female (n = 2) | 3.15 (–) | 3.60 (–) | − 0.45 (–) | 2 (100%) | – | |
| Control groups | Male (n = 35) | 2.82 (2.47–3.06) | 2.73 (2.40–3.00) | 0.01 (− 0.20 to 0.30) | 18 (51.4%) | – |
| Female (n = 11) | 2.23 (2.00–2.59) | 2.70 (2.35–3.47) | − 0.42 (− 0.69 to − 0.34) | 10 (90.9%) | – | |
5α-RD2, 5 alfa-reductase-2 deficiency; CAIS, complete androgen insensitivity syndrome; PAIS, partial androgen insensitivity syndrome; NR5A1, NR5AI gene mutation; CYP17A1, CYP17A1 gene mutation; CSRI, The Children's Sex Role Inventory; CSRI score = masculine score–feminine score, positive value (CSRI score > 0) indicates masculinity, negative value (CSRI score < 0) indicates feminization
*Consistency of gender role and assigned gender
**The chi-square test (Fisher exact probability method) was used to compare the consistency of gender role and assigned gender between 5α-RD2 deficiency, PAIS, NR5A1 and control males respectively, all p > 0.05
***The chi-square test (Fisher exact probability method) was used to compare the consistency of gender role and assigned gender between CAIS and control females (p = 0.111 > 0.05)